0001213900-25-054315.txt : 20250613 0001213900-25-054315.hdr.sgml : 20250613 20250613163007 ACCESSION NUMBER: 0001213900-25-054315 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250612 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 251047058 BUSINESS ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: 1445-885 WEST GEORGIA ST. CITY: VANCOUVER STATE: A1 ZIP: V6C 3E8 8-K 1 ea0245506-8k_inmed.htm CURRENT REPORT
false 0001728328 A1 0001728328 2025-06-12 2025-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 12, 2025

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

British Columbia   001-39685   98-1428279
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

InMed Pharmaceuticals Inc.    
Suite 1445 - 885 W. Georgia Street,    
Vancouver, B.C.    
Canada   V6C 3E8
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

EXPLANATORY NOTE

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities law, which includes, but are not limited to, statements with respect to the InMed Pharmaceuticals Inc.’s (the “Company”) anticipated plans related to its business strategy, and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We may, in some cases, use words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, “anticipate” and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.

 

This Current Report on Form 8-K responds to the following items:

 

Item 1.01 Entry into a Definitive Material Agreement

 

Item 4.01 Changes in Registrant’s Certifying Accountant

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

Item 9.01. Financial Statements and Exhibits

 

Item 1.01 Entry into a Definitive Material Agreement

 

On June 13, 2025, the Company and Yorkville entered into that certain Amendment to Standby Equity Purchase Agreement (the “Amendment”), pursuant to which the Company and Yorkville agreed to amend certain of the provisions set forth under Section 6.02 of the SEPA.

 

Pursuant to the Amendment, the Company may, from time to time, suspend, in its sole discretion, the use of the Registration Statement related to the Common Shares under the SEPA by providing written notice to Yorkville in the event that the Company determines in good faith that such suspension is necessary: (A) to delay the disclosure of material nonpublic information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interest of the Company; or (B) to amend or supplement the Registration Statement or Prospectus so that the Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (a “Black Out Period”). During any such Black Out Period, Yorkville has agreed not to sell any Common Shares pursuant to the Registration Statement, but it may sell Common Shares pursuant to an exemption from the registration requirements under U.S. securities laws subject to compliance with all applicable laws. Further, pursuant to the Amendment, the Company agreed to not impose any Black Out Period that is more restrictive (including, without limitation, as to duration) than the comparable restrictions that the Company may impose on transfers of the Company’s equity securities by its directors and senior executive officers. In addition, the Company shall not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information is made during a Black Out Period, the Black Out Period shall terminate immediately after such announcement, and the Company shall be obligated to immediately notify Yorkville of the termination of the Black Out Period.

 

The foregoing is solely a summary of the material terms of the Amendment, does not purport to be a complete description of the rights and obligations of the parties thereunder, and such summary is qualified in its entirety in all respects by reference to the Amendment, a copy of which is filed as 10.1 to this Current Report on Form 8-K, as well as the version of the SEPA filed with the SEC on December 17, 2024. All capitalized terms used but not defined in this Item 1.01 have the meanings ascribed to them in the SEPA.

 

1

 

 

Item 4.01 Changes in Registrant’s Certifying Accountant

 

On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”). As a result of the acquisition of the Marcum attestation business, on June 12, 2025, the Company was notified by Marcum that Marcum will resign effective June 12, 2025. On June 12, 2025, the Audit Committee of the Company’s Board of Directors (the “Board”) accepted the resignation of Marcum and approved the engagement of CBIZ as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2025.

 

The report of Marcum regarding the Company’s consolidated financial statements for the fiscal year ended June 30, 2024, did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the inclusion of an explanatory paragraph regarding the substantial doubt about the Company’s ability to continue as a going concern.

 

During the fiscal years ended June 30, 2024 and 2023, and through June 12, 2025, the date Marcum informed the Company of its resignation effective June 12, 2025, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for the material weakness related to the adequacy of resources available to respond to financial reporting matters other than in the normal course of business that was previously disclosed under the heading “Item 9A. Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023. Specifically, such material weakness resulted in certain material audit adjustments in the year ended June 30, 2022 related to the presentation of pre-funded warrants associated with a financing transaction and the fair value on the purchase consideration for the acquisition of BayMedica Inc. Management determined that the foregoing material weakness was remediated as of June 30, 2024.

 

During the fiscal years ended June 30, 2024 and 2023 and through June 12, 2025, the date Marcum informed the Company of its resignation effective June 12, 2025, neither the Company nor anyone on the Company’s behalf consulted with CBIZ regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company’s consolidated financial statements, and CBIZ did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

 

The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the SEC and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated June 12, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 13, 2025, the Company held a special meeting of its shareholders (the “Special Meeting”), as communicated in the Company’s definitive proxy statement on Schedule 14A previously filed with the SEC on May 16, 2025 (the “Proxy Statement”). The Company called the Special Meeting for the purpose of approving, in accordance with Nasdaq Listing Rules 5635(b) and 5635(d), the potential issuance of 20% or more of the Company’s issued and outstanding Common Shares pursuant to the SEPA (the “Share Issuance Proposal”).

 

After counting the number of Common Shares present in person and by proxy, it was determined that a quorum for the transaction of business at the Special Meeting was not present. While approximately 60% of the voted Common Shares were in favor of the Share Issuance Proposal, in the absence of a quorum, no business was able to be conducted at the Special Meeting, including a vote on the Share Issuance Proposal. The Board continues to assess whether the Company will (x) hold a subsequent special meeting of its shareholders at a later date with respect to the Share Issuance Proposal and/or (y) include the Share Issuance Proposal in its definitive proxy statement for the Company’s 2025 annual general meeting of shareholders.

 

2

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits are being filed herewith:

 

Exhibit No   Description
10.1   Amendment to Standby Equity Purchase Agreement, dated as of June 13, 2025, by and between the Company and YA II PN, LTD.
16.1   Letter from Marcum LLP, dated June 12, 2025, addressed to the Securities and Exchange Commission.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101).

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: June 13, 2025 By: /s/ Eric A. Adams
    Eric A. Adams
    President and CEO

 

 

4

 

 EX-10.1 2 ea024550601ex10-1_inmed.htm AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT, DATED AS OF JUNE 13, 2025, BY AND BETWEEN THE COMPANY AND YA II PN, LTD

Exhibit 10.1

 

AMENDMENT TO STANDBY

EQUITY PURCHASE AGREEMENT

 

THIS AMENDMENT (the “Amendment”), dated as of June 13, 2025, to the Standby Equity Purchase Agreement (the “SEPA”), dated as of December 13, 2024, by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”) and INMED PHARMACEUTICALS INC., a company organized under the laws of the Province of British Columbia, Canada (the “Company”, and together with the Investor, the “Parties”), is being executed at the direction of the Parties.

 

WHEREAS, Section 12.02 of the SEPA permits the Parties to amend the SEPA through an instrument in writing signed by the Parties.

 

NOW, THEREFORE, in consideration of the foregoing and the agreements, provisions and covenants herein contained, the Parties agree as follows:

 

1. Section 6.02 of the SEPA is hereby deleted in its entirety and replaced with the following:

 

(a)Establishment of a Black Out Period. During the Commitment Period, the Company from time to time may, in its sole discretion, suspend the use of the Registration Statement by written notice to the Investor in the event that the Company determines in good faith that such suspension is necessary (A) to delay the disclosure of material nonpublic information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interest of the Company or (B) to amend or supplement the Registration Statement or Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (a “Black Out Period”).

 

(b)No Sales by Investor During the Black Out Period. During such Black Out Period, the Investor agrees not to sell any Common Shares of the Company pursuant to such Registration Statement, but may sell shares pursuant to an exemption from registration, if available, subject to the Investor’s compliance with Applicable Laws.

 

(c)Limitations on the Black Out Period. The Company shall not impose any Black Out Period that is more restrictive (including, without limitation, as to duration) than the comparable restrictions that the Company may impose on transfers of the Company’s equity securities by its directors and senior executive officers. In addition, the Company shall not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information is made during a Black Out Period, the Black Out Period shall terminate immediately after such announcement, and the Company shall immediately notify the Investor of the termination of the Black Out Period.

 

2. This Amendment supersedes all other prior oral or written agreements between the Investor, the Company, their respective affiliates and persons acting on their behalf with respect to the matters discussed herein. Except as specifically set forth in this Amendment, no other provision of SEPA shall be deemed amended or modified and the SEPA shall otherwise remain in full force and effect.

 

3. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

4. This Amendment shall be governed by and interpreted in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The Parties further agree that any action between them shall be heard in New York County, New York, and expressly consent to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the United States District Court of the Southern District of New York, sitting in New York, New York, for the adjudication of any civil action asserted pursuant to this Amendment.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

The Parties hereto have caused this Amendment to be executed and delivered as of the day and year first written above.

 

  COMPANY:
  INMED PHARMACEUTICALS INC.
         
  By: /s/ Eric A. Adams
  Name: Eric A. Adams
  Title: President and CEO
       
                   
  INVESTOR:
  YA II PN, LTD.
                 
  By: Yorkville Advisors Global, LP     
  Its: Investment Manager
       
  By: Yorkville Advisors Global II, LLC
  Its: General Partner
       
  By: /s/ Matt Beckman  
    Name:  Matt Beckman
  Title: Member

 

 

 

 

 EX-16.1 3 ea024550601ex16-1_inmed.htm LETTER FROM MARCUM LLP, DATED JUNE 12, 2025, ADDRESSED TO THE SECURITIES AND EXCHANGE COMMISSION

Exhibit 16.1

 

June 12, 2025

 

Mr. Eric A. Adams

InMed Pharmaceuticals Inc.

1445, 885 West Georgia St.

Vancouver, B.C.

Canada V6C 3E8

 

Re:InMed Pharmaceuticals Inc.

 

Dear Mr. Adams:

 

This is to confirm that the client-auditor relationship between InMed Pharmaceuticals Inc. (Commission File Number 0001728328) and Marcum llp has ceased effective June 12, 2025.

 

Very truly yours,

 

/s/ Marcum LLP

 

Marcum LLP

 

Sent Via E-Mail njagpal@inmedpharma.com [or Federal Express – Priority]

 

cc: Office of the Chief Accountant
  Securities and Exchange Commission
  Via E-Mail: SECPSletters@sec.gov

 EX-101.SCH 4 inm-20250612.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inm-20250612_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20250612_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover
Jun. 12, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 12, 2025
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 1445 - 885 W. Georgia Street,
Entity Address, City or Town Vancouver
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 3E8
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0245506-8k_inmed.htm inm-20250612.xsd inm-20250612_lab.xml inm-20250612_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0245506-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20250612", "dts": { "inline": { "local": [ "ea0245506-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20250612.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "inm-20250612_lab.xml" ] }, "presentationLink": { "local": [ "inm-20250612_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0245506-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-06-12", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0245506-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-25-054315-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-25-054315-xbrl.zip M4$L#!!0 ( ,.#S5HYT&6#M!\ $>C 6 96$P,C0U-3 V+3AK7VEN M;65D+FAT;>T]:U?;N+;?_2MT<];<@75)R)MG.2LD@::%P!!HF7YA*;:2N#AV M:MEY]-??O27Y&8=7@9;.S#JG0")+6_O]DKS_W_G8(E/F#(.A-G^7&WG>9'=S]366?B09=JWJ^?';\.A?=V[H)#C@@?F*\:6T*8 M88?L^O#B)!KN98^/AFYZ+K7YP'''U ,2XDRU?+&<+]=CD^0YTQ,3P=^%H3.] M=Y[M?*44S+-$G.1.\>L^Y2'c"=[ F? %/E*O!0)_GAY1.PL$#ROMB6O5% M>K#K6(QGCA;?)(;KCF][[B(;$/5EX@'N>LM3PX>)09WN:3C(M,?,F(PHX*V@ M.V,<5RO62^4<"@VCQH%&\+]]S_0L=K"_*7]J^V/F48)SY-DWWYR^RS4=VV.V ME[]<3 "'NOSK7')G,,G9)CWE[I$O';)?,C?D> MZ;3$+S?%9/:W4VPNX=/5*V'#SWA MZ=K.#0-^ ?#A?XTQLPWXOW=DT>'-@%J/F*)\TP,,,WY3OA%J3<[!Q6>/ MF ;)W3I74U66 %HU=]\Q%H1["XN]RPV ZW9)J3CQR*4YAA%=-B,7SIC:&_*# M#5C?-0?(W(8Y#1XS3#ZQZ&*7V([-\#MSOHN,RES@?O&':1C,1E' OV!4UQ_# M/+ID\[EWP0;O<@U^-D .R1?K>9 ?8AKOQ[U6%,J MKJ9C +8;I2P(-N-81WA<-F N6';&Q?>HK7>Y,,, %Q&V=7?D(H@@\_E 4@MS M;N34MQXHIG$4$I2*#$8RL>O@ MP_!CT\ O!B9SB8";91JT9N=CDCCIA\/%-K-64VM- (^.L00"N!2NUP("'$30 M!_-$WZ6? EY=\4SP30JD^.K!9PI]"93ZMBGQ"=*=1N*84>Z[[$!I@5T8$DP5 M?)68'^?*GEPJE%7SJ\V+,4]<(-):Z45 Q0#AEA"*3PI>IY[C1M\^>N]I\#+F MC*W88K8S-NU[UKP7'^E%,Z8-OHYO/XU&)7J1I$F)5TIW?Q.>/= T;7_R6-6^ M1\;4'9KV+L&AQ1RX+!.8*6Z"+GR+Y<_I4%C?N!V8F88WPD6*?^027_0=%^#* M>\YDEQQ:5+\E99B<.Y9I[!'U9=_Q/&<X!.?L'+[UBK]V\NNA<=F"Y1K=%VM?-]XWN<9LTSTY/.[U>YZS[&E!\;O3> M=[K'EV?=#=(J- ND7*Q5=UX% 0%A7WZEH[.+4[+/)]0.+/[-3O%(>*3Y?,O1 M??1FT/._T4-O.?*;OQ]OZ5NMJ_Y@NPZNUU/=FIVX:Q%?,W>PG?^8=B+V-Q': M@]^+#,#O%^WN);EHGY]=7+X*CYW[+O>I[1'/@0=U].%(J4("1.VY_J(VJ C&[I'X.O23J7ZFXD<>E:XM0L&OK-'UH*_&04[ MRKA'V!0&$U=\S8SU72TMG]LI^3P7?EE;.FW9@FJ>7UWX8[M7Z54>):@R[P*^ M]]S;-6#V,8P=&72Q &B9G13D4C%+D!/ Y0X^^#8CI?(&P57^$;*=IEY944\& M41=L:'),<7D8.Z_0L@9OW[Z?G9Q\>ASQ$L0I+0=PR;5S!YWN*1CZ\_>-B]-& MLWUUV6DV3GJDTVT6?B*AUMISV(+(+*"4-)TQK+P@E)/>A.D8.AG$M$D3/%MX M9%U[<9@27I='^Q:#KRP+$*)C;CH'4H!_3ZAA!'\_&HR8PQKZH;IC673"P=L, M?A-AR;ZG_/-]STBYM8'GVI>>:Z$6^:Y3YGJF3JU@<^ !AZM6RG^LH(;@Y-AF M\@,Z-JW%[GW;B7O*1725,\2BGA"+.W,+-\;\)%M2SLO>[=9AOSKJZ#DB,IKO M9B-$LBJ6[3@X1(O$1\!PEC_NFS1D^1CGJU\] M8XD":?Q*4H0H7H7A@+^FZTZ"KI=TWE%I+%W(ZUU$GHW.K*_MUEFM MIC^=R!F)T!5 Y YVMO.E:GF[O+7S0)+#/^XJQ9I)BA='_YI0@.B:GX&[[)(/ MX"USPQ0^^W[?W3S0P# F-.;Z4_GXD9'C2=0I+* B9>5-X*@>OZ5'_$K[1'43++5%635W=>0VEVK%/ MP74]%S5,G?D".HYB7+B/CY]N;.[;8.S1F!I\% Y?W1AM)XQ1PS!SB-Z$7\_<2V=F9Y-\V-6'K=+IE];1T[.5I?I* MDD?+YPX^43#'/N!N!5DWR&&A>:^@_QK$O=]#?77R5S/)+R/$;-H??>F95=YF MYV>/"RYB"3 ,&(/&'62!I?S7UFK6D$_E#IK4I@9]'5G_!>G6S*+;N<,]:GTQ M)R*VSZ2>VYU\VM*_7CGC[:=+[O9*\B0@ .&M-TFEO=1 <7^\\&OIS#6U.TR; MG;NFK9L3:I'VG.G@;$P9.1N Z\CXO6[S,VBAY]T7$(H@I7XI;_?E:D,RX_F_ M_]DNE[;V. RSV&3DV(S8(NS9($!:RT>'6J,NHR 0!J!K+2U[#25[:*8:,&ZU MM&U;O;^V9^>>];G_=&E+5/7B:^8.ZL7J"ME:7ZI%!M[=B0/R=([;OBN[P.O? MK^:?*_1VZ^F0EQ-EC/2Z 'U])[]5+F[](XH77<0O#4 \YGV@GEGJJF/6O9\D4;++[Z'$)W] A&#,PR MED$!SZXS<4W,]?2=.>DSRYGA=O%+Q +9SG_4!J8%DDY,#F+O,=L -'@.X>;8 MMSQJ,\?GUH)PZIE\L!!/J@>< 4FR'Q;)89XMJYL-T:?6IW;UO?/M2>7A/N.8S%JBT;7 ME!9-U!LSP4+:[FQ5JWLK->FR3_*,*%0PP5[C0)%)K"\"6[9(M5Q3\I'J5< 6 MA;72%FD>79!RI5B @:A_7M(=^5<<'B8.07J@!W&.#M2RAZ>@54&U6BO\AM)U M^[;^J=[EHY>0A43S]#),/UD0(H" V21$RU)0JE+8<4P0$ITZH1A4BP4Y=->AX^!" +C*D78NOQH3H]\='C^]7^@.@4A4:5?# M]I,% P#+ZS'([C45I:J1+Z_UUQ\F)G+LOX+R2PA*.UM0.IS[S+U77#[TSQHC M[[#_U^SK2XA+]0YQ68+PS0E-A>6K:_K#A$:-?5VA^?'I8EZCC+J8"W';)*L% M5^@/%87!]O^)@93,6#^E$#$;F1[+XY88'OJ;N?2U6V4NL>E,MO/J(Z);E/,' MEW-_,)O_NOMT*;()Z2W&?<=:NS^+_&R[_.DD#EI1!859H*I =@$T^"02\ =4 M"OJPOZ'K@.I#.7'<7>(.^VOE8G6C7-G>*-=JZ\MB\'/Z3U8=$E&J;5$J]P7O M9QO(T:?;VG7MHW=BEYZ>F$U4V]/KYC!1/@8JR"-[&\ ;9$)=,J66OW0(]X>Z M_7[!YJ!5Q%%2*H4TFS+?OA_96]91;3!^7!HH09E$43RQJ.@J_]W1?PFV>E7A M(N#3P*=9W>;?/[LV=7[8*;?J/U2B1I6459\N;V7)3QRN'.@V;M!O*^A%>IX# MZOB4NK?,(ROO[U.#KYC&^B?,M)?$%WDX^&I6]#G3/1;)I/EFLD)4!J< M6YQX2$!]S[P1NKG!P02##4Q;'DN0&<1BC2P?=8I..%7(&NYR:T^F$8/1L Z0 M9H*G&K .(IWEW!%-]\3#?!2F*3PB=<1G?J(H=X M4"E7EP0I :[#3X)GZL+3"_<5@U:"I2ZV6%K99?0VWV<@8@#=1$ ;7ZN>L12N MOW*M",WQ%>/T?M.DCK6!M*_/3QK=QN79Q=^D>W;9_@WZ:D(,7J(/UO1=%_.C MZAPXGF51/1Y"6U/3Y@2;OLK%/6"?&1B8O.4XM\KB>"*YRL6 TIXP6.!NHFD9 M@_X6#1\# MR*= T+)!B#4/B=Y7$Z.N" "+SC94WD1VL2$F^[Y'((87UMLRQV(/GK-!HFU+ M PUA_@2,*QI97%4U;+H$K #*M!6<\-F>,*$3,BTC$ MJP\-Y"[403KEGN@'E0L@!GW+XQL: \X<"RY!FHW1M>$"_PN(] P&H.)=0$A% M7(YR[H\G,I\/XT$*0.D@@ 7RF>%NT%T#W3IF!%9$DJ('-G/01^(^T)J&K!UA M42%V0U/?])EELFGXJ"XSK!YC=$N.08T!!3M@ NU9F+ MJL);Q*@J+I#@Z+%A--81P[O)(2'3%9@33L19SIE#H"-@(N M8Z9D+BV0T-A $TF^>X*'ID )XC%[S=9\!#,$:(1O_.M=^0@WB_'D<%Y=@& M#S14U%4'.FW,7ZBV\Z/3R7\+-=.&H S@!%>I6"+[YD$;SS!@VR%H']+")(WX_.$T+ GPJ#9,P,>23(^^F"9*%VGO' KO(W^1^=X"^!=SP41C% M]R+=A>JV/1^9?3#=S[B]E_$KY0'24#8?(Y@O[=N^1B!X9A-YCU!%WB.T(;1K M>#4,4/)OQ[V=@NT%8VB+6IPFL"-MIS29)+RM561I,(G37Y#V-Q_XG)S[KCX" MUR7"W--\QW"-E/>XD4@120CV>>,MV=D5:\0O,!/-$@&JD]P@O-&!ZXPU&IHK?.'4"T87+=98@Q.0FZK0IK@2D0Z SU1MSG5ZM&-!"9Z-[RAPQZ6)&CJ8O:08#XF1PK^6FQ,J M'3P4F^G@/%)WL4O6&NNXE %0"T=0PQU;#EX#*CUYI3!LQY[X?8C<$D$%.(+ M>B*TBP$D496<2'*T EP@WA3QQ$:PMQC8S@3TE6-K"M'-*.,K_N[CG6BFD&+N MD>2@/71RUP[7(]& O[D/,:>DSAV$@X'GKB,"2!^I'^)9>]@#(VI9PO]5<2LF MKWV1X8_<61%,14A%AUAXY1#2BD,;XEJ/] 7[UU'C25]93'(0,"$ZPV/A^3$ M.<;T5N:V8VZX&BLP"$(S"K&FFZ[NC^4+" +N#'7/@LS@,9C08!MB8^ 46$R4 M( MY3DTB\XP].U_5?D*46HPD0ZJUH"[B5(E.+Q CGP729FT%7>HNLA,"+X<3QS. M!(Y"U&H2M9+702+'CDP">"[>)@,>PUIXEG!# 8!I$S!4*D4J7 ,#5]=,X,3 M22D5=1I7 !_.AP9I27L!RC4%&J8IQ,L=T-],"G;H;C-ICV,I(]"BJ*\-P+@. MH:;TW#@#%8)Q$8>@&H84T&6KM3+ M1L2E:0:%J97]E9J2VK;C!UV/L!W!U8%L;ZQ0J2;74.+"=3+$ )=(?ZKTC\K+ M@!8QQQ!>X]$Q"_A@X.%EY"+1$H-)II_BM)"3@))1A\.DTHE/A=9IL(A)HB)3 ML'#L.-D2>MZ^BW$I8G:0=4<=N4,G 1$,R!V/40.KO0=4UA O(2_'Q-1PF,RG M@2B+-(%4[E0J C#HP(/@>IB3Q $]U-TJP1>>W@MG!W$3\B"TO= ZDL!(=RV M#V#^YL.V@FL247(P#01.#@8,0N^H-*J0K/#2_ Q5@\!.%I%UA[D'IL4P'0@8 M+Y3D(TL9$2V6$1$*9"94MP \>,%/W#55D\ZD1X.?-5%3M,#JX0%<4MH23G^U M0!HPCTXGH)PL\SLJ/H%\'_.=J-^E9 >M&)H +8J91G3*XLEJP#,2H!_Z^1,YFIW<585$>R13]@8]WHE,[E#&Q6?]:"-+M=HDHL6 M,]:4];C$6TDD&O8(7BB]2QI@HDP]>%$)HJKK( )*B1I:\)0HZ/ZNU;WG9\5^ M+(_VI"3:2^>CSDY.3\\>O)Y]=\MP!?JI*1X'B%E"HCAKUD5I8 M@B0]A0"N#;0)B9N@DX[LC'+I>:#5 JNDIA*^I/H="RL( V"=L,& 2?! MG&6NT@#_UA,>/T;@3%OA>1XZU#5P,ZW0TWQ2"DC,LU0\U'4V47&=VD;H3 6( MPT(;7@DP5<.8/51E-@19\)*RHFG035@=DQLR01$[;R+]U+!U"4PMV&5L?9(7 M!7 LV^#5WK"6Z.X7V*L4%3Y_#X?.576:$-& (:!0*JD1X%+3P7"BQ1-1>-3_ M%0NW5^ /AL?1!^)OF#)\5?4T$510 UT@%B1!,+X7F11JXJ47 &20'4%V4'(1 M<^E@^-@QY.\R-HN5!,';$JS.P6^#F![&QD@_D3<"68A!-D=N##5XD@Q!\_B#I'QA5\J093F.OYPE*6^D!,#UI61)$M&=4 T M4[0*1%IEA8;E7Z_ =Z0,R%X(P6Q9_ F,JTUZ69. MPQQ8PY !,X,K,>^C)"-N/^F^"O;CREAM%=0 M3+1K M(YFQ#/ H"W^- L&W6+J.):/I\Y ; K2J]=.:JF';H&K3I?U2$; :X&N%NJ\4 M-/5^ A![:[&1S ;%D8MNE)2NH*P3CI+JFQJH4*2M47"N6+2C+KKD&/9R1S?%4S(5&= ,-1>FYQ3W!VPTH*8Z5242>"+_I8IE M:"M-@ZFT:("AI&^H'=+%*;;04-&:!7(3- ]%A0TC2AM&Z9=EW"$[8-K5D-!3 MX>\FM.H_U(:\J@FQF1F>D@F>!SD&AV6!E]0YV9+59R-J#03'2/X7O">%JW]<3<&WR4IEA"2 MIWPOI7W&HI321T6*ZD:&)@+B%7N,NXY:ENLH;;V8(O -U1$"81>#$B&6C/"N M+? 51:DP4(6H-\?"3H#PH)&26Q4B**&+T\3$0@751^*>0) U792,E=<85F$B MW&Z$9E38U"Q%;N+= Z($9YKK<5,>@ACCC:#Z(6IB<6/X_$Z&= )(VHB2NQ>: MKFM+Z_P.)Z0N8TP0GE )PVBA\8/$+N9(M3L:VD#<4*G+_E9UL5PB48MDP7(8 MA/R!%EI).)\N3K(*3(-E3?\A=9+@PF3M:\XP2H97"%;A 50ZN@> MFD_D,QZ!"7')-%$NI:(+ #5>E*87#PEEJ87I<3,XX;TTL$ :,10RM:$-(H/& ME+Z,I\U5PQ$IU0LELA:FU/P.>VF%:J-N)>?':YYY0N0"HD,IZV MJ7,!0ECS7\IBQM4B^NC*!4KA AU033FYLF@]4%DY81@QBP,6TS6B4KX\0DU. M3"Z>Q_-7G-3JE1I&>*@?Q>_&NB3Q!-A;9DW0F(I98(5R\0^9VG'#BFLZ+R5L MKR&+@[XGSB#B>0'A.[_;9"_WX>N@ T%_T#%/0 MNQ6L_?$M_VHQ7?^>.9;E()@N.L\\"ZYTC/= MF+=3?.ZMM*)FOJ>]+@:H^H2;X;(US[-M#)O\'OJBF"6?_:'CGY$.E(Q*^=*-:8^941AYX]@)G0>= @IR.K%:0Q2R]^79HS[S9HPE M0F1Y)JE!.AURWMT@)Y9(83F8D4;?Y1X]2* M1%XZ7QF_6$':D^B^@#:IOB/Y-!QO\A4O90?^:REI6BWI4OD-V M#7OU#$.EHE3$V[$Q^T&N#R].B.$ .Z">0-JJ>"Z9Q"V6, 'RLJ^C6F:$F13_ MN-NAO5)K9'5*[^/JM[I:^2?L]DF,2VO& /N3)GE4^71W;KV!W_GW71,^=_77TQG$]GMWZEV'0G7ZI7 MVW11>O\W'90//WZ]??_>/30.:P-ZJ5N-X_JLU]RY[)Q:I?=\;%ZP&;L=3L^V M=V!-Y]C]](D//T_H]^%\AW[_JV=O==]OUQ8?VA6#5C[6.X?>T9ES-&OKW^UN M\>+P^/3XXG!Z>SL=<<>T+JJ;HQY;?+AETT]=RRE>[WSH';G\NEO^\JV_6;\N M-KYWNA^OA^_>28QL]AUC@3]'WM@Z^']02P,$% @ PX/-6HQ,!X]K"P MI#0 !L !E83 R-#4U,#8P,65X,3 M,5]I;FUE9"YH=&WM6VMOVL@:_H[$ M?YB#M%4K$7+IMA]2BN2 VW(.(1P@NXJ.SH?!'L*TMH>=L9.RO_X\[XQM#*%) M>K9IHFTKE8L]EV?>R_->3-H?IJ>#3KW6_N![/;PS^M>>]J<#O]/>=^^XNY_? M;I^<]2[89'HQ\-\VYBI)C]GAP3)E4QD+PX;BFHU5S).FN]!D$Z'EO(&)F#K: MG#=347B/R6]8S/6E3/92M3QF&%Y>F*DT57%^+16?TST>R9;,S/+-X^WOG?K#'OY/V?0,>WO#WLG%XZ'Q M_WW>GUZPT?FX^\&;^,Q[/_9]0OB43"VOZH3]AI9K(V4XZS].%8,^B\(],O6F?=[Q8)"'^I^W]\\XS M;2^_:+*0IR)DW# U9__,$L$.7S;9T<'1JR9+%:,E)BE/PMF*^7]D,EVQ4::# M!3>">9=:"%J0;>TT\4?>QB;U6G67G@A$/!.ZV.G7)L/JV(/-1'HM1,(N/-;O ML]&PR0;37JO)..OR%<3(^B;".,/$9Q%#RI&,):V[Y#I-A#8+N=S&TD^NA$F5 MKN*IUVBS_O#4[['1!V]\ZG7]\VF_ZPTFN-JU&P8J7O)DQ92^Y(G\$YMD$+JV M HGXM3T(?1YI=2630-#W$RU3:1:LJZ(LGDG>!.R$AWP;4]>M78'4=)!2=2DP M5+-KF2[L\@7\)MM<8H032V$V52D-)"B32Q)/D%F!IW9>*+4(4JF2$K6;WGH, M&[Z+SKZ___S^P1_[WH16MU*JUPZ/6@='A;#(G-E2:-B:J4J/_(.34ZU'I0NM MLLL%C)G)Q*0ZL^XA$W9-I@'-&*"!7F#O/]6PK8;AV>_8@'3Q[FSLPR4@MT E M1L+O>-5ZYTJ+2T7BY+GP>4%%P+8DCS08;NSM0%V)A.,.@V,)MV3*);30W%"F M78(8:JZB2%V;XY]*(:4]K: %#G _K37V77WR-Y^SE]L MC]@I&806WZ1\%B&.6>Z"NCD[@?X^L;,L92.<1H44=EJLEVGR05(H(AK8T4YP M(YK%90IT]=I@]YJMF82U&112C3 "3@:$UF)2!$_:!]_K-7%%X]-%'A9S>##>E-@] M@?XP\E*ID,VYLU6,-%FPR!$1JY#1)\A@C.%ZQ9Y[+V@WF#]?Y:'6!)$RF;:H M8V#4DD< EBPS2#7 #J"OF+LX RX*A$XJ8B1 S1TK72\D8.3 K00)ATJ;^>&J ML-52)A6Z+%?-1\X@%'P&,OJ@YO5:51@0U_.3%^O8AN\F6RXC)^M;U("!2(8@ MIB#-2*<5Z=UOQH)'4;V&,P%<$&6AH#":)8BB@IGU)#+(4JYS'MAU%,R/,-MQ M-P9H@=15"TJP<'HWR%J7#0B8OE8H1L3\DW R*7H1\.^+7:V3N M.3@ZEN:)F0N][4*ER0K7^C HJZF0P'@82G> #2AK:2&+P"1MQ>6%5]9#ABZC"1U7E(*LR!]K.]!Y@L&31&68 M6D1+Z_I%/&SNSD2@!I))N-[H)B/M5'ZN:Y<_4>B5<2Q"B4\1DO\YKKO]JZ": M9=FV:3"5J38-@ UNIG&Y-F\7D"W9JM99(_+$D X[EH:X)^94VB!69K@!#(&P,\1\C@.5[9ZG819/SDQ?WC!38FOHHVQKDCZO ME5.()MK/J)JA+C! "0Z^*2NF&\JD?%\"'7$A)3Y6=<7HL@'KIE'W*94I]H2% MBE+IAE/Y5?;W6C#[-8 ";$[FV/)*2 M6)[YZ_6F%.UX'AJ]O'ZRI^;K3"SBUR_6-VR 1.UB_22&B)1S 4):D3Y5?>MS M;XL>?KS@5U1_@CO"+'+=H2O81!BM*O/V&;]0RJ6"M/->- G9-@26NNCB\2!0.EPGZ=O//6SY0%_H*!=*?RHS M-90&7(1JT_@47.8F#506LXECD4/=IYI9X>V%VNS-K(P9ZO5 ML!.OS[$0M!L0ET"L-R(&%1?RAROB,TYG3+2R;BV2,K!\1,IC0IF 4.HB,Y(RW;5Z01KT&3R396L$9UI,N/UVO:S># "& 9'W[ MK@TKQ[3>8;OAX4?P25!F2-9+Y96,((C\E(B?VCXYJ]2(FR'R.SV4^"H/>OAG MR_\9^Z=>?]CSQ^SL'1MY[WW6'T[]X;1_-O0&@XMZ;>"_F[*3@3?\UW\?YWDS M]OO'WAY[)T44'L-U+L4;+/I')N"KV)OM[>4_P6CW^K\5P*K;'1[MV.\U79O! MY84NK[FL^K#U:DG,#C8&HM'FBC=JZ/8^=MT!8*8%_[0W$_3LYI@M+>HJJ-<[ M,!'0K]VR(II]DHT3QX^3^CJJ1715244EWP? M[;?#64C8Y.[@^!BB*^-+#;XE/# MFMO='1KW0ZA>B7W:6U]DW3."/GS;>+F!<^]:4'_9L1W,_]W9<+IQW\@_A3M, MH],].\42%\?M?1K6J>Y Q>^W17D'%K#5EW]3X1CLKX/<:FF]/OBEL1OWYKA7 M]QOVZ_V&O3PLQU5?O[WT[Y#XR>J8[1!J56M'I6W=3>[[9I_YR#J8UV)>R&/S MW0\T1&5UCR-U'A?E5*:1V.5R6RA'R#6.;O^V0,@_2L7'PG"MWI]6++[ MORFY/_S-GTS/QD^%DS=_3/>M>/CQ3>%ILFV'2C&46I&@%KXT]&C@?:1FU&X: MC-B3.4P_-?=@L#O6L+U?VU8XY0F2;;U+/G\?HMOZZNQAX](7E0\7A/X'W8=' MY12[<>F]2&Q[<.1^)ON#*N?K\J!3GJ;L1 2?4",\L*/NO&@SH9UWJL@>7HY% MKO,5U')J?]U]&Q,\PF/]O]#$V+3%?:6YM960N:'1M MW5=I:^,P$/T>R'\8#%MV(8>3'AL2-S2'>RQ)&QK3I2S[09''L8HL&4ENFW^_ MTWBGP7#0+A:\4[_3MT_(/UYP%@S\ME==/&UO M==GM=2_ZUS .K@?^H1-)89I0P:5,B"@M&DHP1L4BQQI:T]%[ M[5J0$#5EH@GY4+<%!N]-F7 VM4V*36/CM+UNV[^/V809J!U4:EZU:V&/-N'P M)M.&13.GO2,F.FUMVLN/3"#4ZB6HN_7][0AIJ"K@*T:A4X%.2!*]:8=G8H@A MC&*B$D(Q,XP2KN%,T,JF/=?V]O9+T&CLPT_4!DY06AL"8[-QSU=$4)G=HBI! MM]+;N+L>$20D<'70@UV_\(G-IR;O/@[!G-VKP67N/5_6+>";/A(%.>G, MR::Y'20:Q$R#_1H)5(J(J01,3(S]0:"9F25#MMSE.OF@]M0TQTL4"1:(L HPBI8;<(CZ1NXXSU.=MT MA6H&1F5\!C.9*5W:CK"JNKK:?4NZVQ'3ML4SMAP 5_:VX9>'A'$0-V2:$G[$ M1()A.C_W%2H3^&4IXAA#5(07"_Y]JE!KV!$AT7$+1HI)Q>6H+ )JW_.O !Z71TEI>[NKW97=N)Y'(7C%7!!&FY;K5"R J<=\0L=-ZW%@?QG88HXDXY?@"86)MK 6"3$' M-RR*0RRQVL@\U<&Y4_& ;1\@^X2IS_ACOUW(3J2,11W"V6SF4/:*9HQ/A>.Q MZ##!@40R$85:95[)G\/H72*\@@Q?^K_8IWF?#"<)_9SE^'4Z_!8NNG!%Z-EJX#[W6]*X;L%[FLB&\"8X04+6@HFGI_/+T M9C6'\3&L5BHN''8[@Q1G9<#Z/"1TN@WN7EQ8;:Y!R5;H>08E!NKC#9S GC-FKU!M*'SUS 3 M88\1B@MP@,0H%E MQGVLG+M5-5HACC"5+<:C6QR@)%2AO"0H) '!O@4DXF,L=9N)&'GX;4'3KHA2 MIKI:359NT;8X)JIM"X,RZ3+7.0OQ#Q4_T LU5CN]Z'UXP]3E8 'B-ZULN:)G M%'T<$$I2[_DDN<#6BCTDO DZC*^?T*)L!AS251;KUP&6>1$:GIOQ0W0 M?H0%X+]+/$2C8Q-7%!S^QXP[6K^<:@.NCY9ZWQR_ALJ6<0EH:93WW:795Z## MO%1J#T6_V89G:Y/M5NV:Z\R%OXSTF""6)W!<$(9W0A [;O1M_L4NN%[H%CH[ MU.F.+\->IULY$(=2&,O)(:Q^1_XBAE3FJ"#6RNE+#K6$%JW:JHXU=W&ULS9U=;^.X%8;O"_0_L.Y-"XSCQ%DLD.S,+C*>9&%L-DECSVS;1;&@ M)<810I,!)2?VOR\IB;)$\4A*BI*=\0/<>Z/M!SFR?N.="WR_V([:UM^\^&U'U>J-E[+3PV+9)?) M"8S$VJ2JHF,$SO>03PQEW57M/&K42]5HSD6[[6IFS.M,272TYB^3F"2R[NEW MZL-8?5.OU-U"1ZET MM*%2H594A(V_+D8_YAKTNU;]Y^/D4(N#CI9+H.V&L&PI:[2TH%GLJIMMIG0O MU\N"Z&2+(;./M00IC>,.OI [CM7.KRA>6^P;Y:ZZV&I+]W&C,(A.MCDR>[G2 M("7RUR S>00J0\+!YO)%K<[E,FE@8VMZG_"T;'?Q4XF# M1 @'9-2%K"H$"! MW(&P% &:F3S$*S#_(E@,PZ6F] -+RZH=E4H6("BFMSY,E-X+)+.M$ W7\(P# M2YW=E.TQ6]V?!71!@-)CKG77MI W0/$T UVR+,GVZG&ZF^UF182E<6V)*S8@ M>E[?)6"9>H@1;(XI[!=+9U;)@";32@,44!4V)T!6)1BE*N1E'L! MXTXD&RSVBR3JF2K:0K=H0$:;;)BJ@. K %TE&JTF,]\SB1+O)O'$M3D(2F> M!^^A!-2[A:7'=I,90!P0.MT. 8)D$&I&^01ISB(NGGGM<8<9W\H!<#_C,;Q" MZ8ER"]6@)C31Z@P)"+ A/@',&J$?BF=2$%>O\>05(%6#%^(NXE@>J+3\YSIA MY 1LOU7KEJX.NTVF+,* 2(+= ?R4R@_Z U(QZ):% LWT#4V=^H=F.A2::=#0 M3-\#S?*5!P+-Z1N:>NH?FM.AT)P&#]UK)G)C[=BR5]M#V>#2B_( MM*U:@3G(PL.EY:T/%A6@UC,JQ"%R'4W*T8%P<"(T"QVULD64U4?U\K"Z.*VH58/Y]]K MJ?'Q15;97>C=(V?P P)MB:N>ALSIWC;+@^AQP)39Z[D,Y3I/5^-5AHG4/GS7 MRIS-[*:=:B+7!4'TKNFF-4WK]^9M(,KGG&=]LMJR\RV-[;A#0N>KE3INZ MQZVB('J_RYE)0JE%3;%C+!:<)E&2)6S]JSSY% FVM5!L &8,EG(RQ!_0"?3OZW^CG24X^Z_X4N! M5>[8Q7ZSXA3(/F55N8*@PZ+FP"() @78ETG##4>E%!5:']FI&F8MS3'*70%@ MM:6[OE$81*?;'+6^_(V^]C3D7^ZB1VF* "\DV&6NAWZ;27/XKVN"0*##6.ND MI)0BK?7Q0L)AREKW+P+6WA8!ZYY%P#K$1 AU:7K2^G% QB_$4I_8?R5+0A..2-Q M<2W%=J>H6^_VB9D>V\V'9@!Q$#@-<0@\.J."QD\J"NFP\DJ8%Y*^<;IE&1;Y MN^3"-C(!.K?D #:;Q!BB@$BQ.P,(J<2H4/MY0;O('E$MLHK?'0(;",D=OZ[= M:=IX:]NJ#8B93H/0.]QESH_#VKB(\O2*94;4[T4D+^0+SG#I#6PO)'?]4F67 M:?-M2ILV((0Z#8+O3U8Q*E4,UDQY2QDC9G*IM>8=3XD;*O>)8UH6V[EC*DE M>-A\=620$4AKO;"PV&!*/V_3A)$4GH@,E5L6K!:;+#0D ;%@\P6PD$N1UGIA MX7)#Q%I.;S\+_IH]EOE9P;8!:K=L=%IN,F*5!L1*ES^ &1V"BAB=4MH25'7U."LD>"+LN?H:MG M@B_J\?5+(U&D7H@H5N4LQL*&4)?8^:^.@(9;OSW24@8!4J\]^'=(J@BD0QQ3 MSL_20Q9 $G_> MWY,'(M1[!TNRRS[+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>B>@5HI9X1 M*ZM OZM*4%Z+[??+ZYNNY2>Y66^2?ZUP2N26_P)02P,$% @ PX/-6K#Q M58%9!P V5< !0 !I;FTM,C R-3 V,3)?<')E+GAM;,V<75/;.!2&[W=F M_X,W>QU"0LLN%+8#*>ED2@M+:+N[-QW%5A(-LI219)+\^Y7L.,V')1]N?. " M@O/JXWV.+?O8DB_>+U,>/5.EF127K>[1<2NB(I8)$]/+UM=1^VK4'PY;D39$ M)(1+02];0K;>__7K+Y']N?BMW8X&C/+D//H@X_903.2[Z M)Z7GTD0JJB)'J M7?2-\,QMD0/&J8KZ,IUS:JC]HFCX/#H].HZC=AM0[3OS M3F>Q6!P)^4P64CWIHUBFL I'AIA,;VH[7AZO?XKB%YR)IW/W:TPTC2PNH<^7 MFEVV7+OK9AUN MKWW2/5KJI%7"SPDJR>D#G43NKXW>IE4F4IK,9T2EQ,6LX[[O]*7=)6UG\Y(S M12>7+:NS]??>'I]V>Z[VWWZ9F;L=J19V=EN>*:BI,;O;6;M@I0I?& M[E T*2MRS;^@;X89IU_O,=VH[7:O++7-V8^%T-58&T5B4];$R9CRO/X?5K,GZ330 MJY+$HZVQNE.[BOT^;,;P(] M43+UT5F3D)Z.;H.R331#\\JVG[@^##B95N/-2 M W9'">3;0^5;X:UAS.6Q\T"GS/77=<6=1=Y0T)\]\9488JOH*0/A #8;_%A.UQB,3[41&AF>,# M 7ZH!A(_1;WP\'A$0CZ:4_S%8"_>7;G=WMJ@;/? M*@+$_^=KP7_@%BD"]U0QF=A3N@*P/Q #J9]A4O-&C@=VFP[@KY%#D*#EGK4U4[/]2HL#0M\10Y"AI:(W%AH'W,Z5V M.A,<5?QJ*'*4!+3.9,/,;X1A9N7N^W_)TO'/&Z>[K ]54,8H2:?/% K;\DZ# M,.YY1HCOOA+*&"77#)E#X=RW?A3A0Y'0Y2>Z"H$^D$))H^2807LHJ.\52XE: MC5ANC>(E#V*&DER"Y*"(8BEFHN MMVX7]V5FC\=57R;!(;VF(#0<*/GF"ZRC!.4J22PNO?YSRP3MAD)1*0<_(\(+ M0,#F*\'>>QGV'AP[2AY::_.58#]Y&?83.':47+36)B;VOOUXIQ[EPO,$VBN& M(D?)16LL8@+/SS1WZE[)9U9,C*JC?E "BAXQ10V;1=WABY,\9&\OE5#>B.EJ MM3E,SO=2&\+_8_.Z*\EJ/90Y8N(:,MKT#<8B[NZFA6\JT9X$RAJZ8'7S276WD-_ MZVOP##:4877?1L,8ORMF; _Z,DTSL;Y'XWDJYI%"\:*D?T%[#:,>2%C)+L^8TU3/A>41=I:B^[\WE<;K&!NIM,?"-O2 \ECI+K MU1O%)3_4.J/JI?PK2D&C@)+V04TW/<[0.+/#WJK;&S^Z%3.>4>9 !66-DO+Y M3#7,]HM\5,2MUQNMTK'D_N4AE4(H890$+V"M8<@[_:C&NR>!@D7)["KM((T) M-\MX1L24^FU$R/I\I)+;%W'![1-V-.9L2 M_TJR8 'P.AM,X@&K3:_?RY?\N*7<*LW[,; ?JK%[I%#@.$LD0_::1ITES-"D MZ-* "2)BFU)MUK5YLO/Z4M X*RA!)I&N;W_G7+^2*10YXK-#CSV( MN*\$%#SB0\2P6:3Y:8:Z/K-G^H$8LNYAB+^O!)0_X@/%L%FT^?.J;T\\4QE^ M9KXGA-)&G I;:0T%\B@EG%]GF@FJ@V/+GA *&7'.:Z4U%,@W*553.ZA]5')A M9NNUG2'8G@)0Z(@S6X-6<> O?ZXC+]:_!5MHTD-]*6@44-)5J&F<<^O6 M2O[@J75'!^6-F)A6&<-9,Y6-.8L'7)+@=?F.#,H7,0NML(6"]YJ()Y7-3;RZ M5S*FU#T^T9NC#9 0 2N A@0Q/WT1"IS;!3)-W6(B&3^-9M:TOLM,_@93V[_@ M38-@.6AH,!=Q HPC707IGPN]:'*]>J 3JMPTA4>Z-->VH:?P11&@.#0^J&\4 M F.H"--%Y\#7K=W@7E);?.-^N1>QVBW_ U!+ 0(4 Q0 ( ,.#S5HYT&6# MM!\ $>C 6 " 0 !E83 R-#4U,#8M.&M?:6YM960N M:'1M4$L! A0#% @ PX/-6HQ,!X]K"P I#0 !L ( ! MZ!\ &5A,#(T-34P-C Q97@Q,"TQ7VEN;65D+FAT;5!+ 0(4 Q0 ( ,.# MS5JGSV]D_0( (D/ ; " 8PK !E83 R-#4U,#8P,65X M,38M,5]I;FUE9"YH=&U02P$"% ,4 " ##@\U:^K<;_"H# #H"P $ M @ '"+@ :6YM+3(P,C4P-C$R+GAS9%!+ 0(4 Q0 ( ,.# MS5I>N)WI_0H '^& 4 " 1HR !I;FTM,C R-3 V,3)? M;&%B+GAM;%!+ 0(4 Q0 ( ,.#S5JP\56!60< -E7 4 M " 4D] !I;FTM,C R-3 V,3)?<')E+GAM;%!+!08 !@ & )@! #4 %1 ! end XML 17 ea0245506-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2025-06-12 2025-06-12 iso4217:USD shares iso4217:USD shares false 0001728328 A1 8-K 2025-06-12 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 1445 - 885 W. Georgia Street, Vancouver CA V6C 3E8 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false